From Genentech’s Souped-Up Herceptin: The Odyssey Toward a More Powerful Breast Cancer Drug:

rscheller
rscheller

Richard Scheller is CSO and head of therapeutics at 23andMe and formerly Executive Vice President of Research and early development at Genentech